Founded in 2005 by industry veteran Jim Connolly, Intervention Diagnostics, Inc. (IVD) is a privately funded healthcare R&D leader dedicated to revolutionizing medical diagnostics through advanced electrochemical sensor technology. With over three decades of expertise in diabetes care sensor development—including the successful $200 million acquisition of PTS Diagnostics by Sinocare in 2016—Connolly guides IVD in creating innovative, patent-protected solutions that redefine how critical health conditions are diagnosed and managed.Our MissionIVD is committed to transforming the global diagnostics landscape by developing cutting-edge sensor technologies. Our high-impact diagnostic tools target key blood chemistries, empowering healthcare providers to monitor general health and address complex diabetes-related complications with unprecedented precision. Innovative Technology, Transformative BenefitsIVD’s electrochemical sensors deliver rapid, cost-effective, and accessible blood testing, outperforming traditional methods in precision and usability. Unlike centralized lab systems reliant on expensive equipment and infrastructure, our platform provides lab-quality results in seconds from just a 5 µL drop of undiluted whole blood—ideal for professional, at-home, and corporate wellness settings. Recent prototypes excel in detecting over 20 biomarkers, including cholesterol, HbA1c, and glucose. Key competitive advantages include:

• High Precision and Sensitivity: 14-bit system for accurate multi-analyte detection, surpassing competitors in comprehensive health profiling.
• Ultra-Low Sample Volume: Enables frequent monitoring for vulnerable populations like children and the elderly.
• Rapid Results: Actionable insights in seconds, minimizing delays and enabling timely interventions.
• Environmental Reliability: Consistent performance across temperatures, supporting global deployment.
• Versatile Dual-Use Design: Seamless transition between clinical and consumer applications with EMR integration.
• Unmatched Affordability: Under $2 cost per test, plus scalable manufacturing via laser ablation, plasma treatment, and micro-scale screen printing with premium gold and platinum materials.
• Core Product: A compact, 3D-printed handheld analyzer with disposable sensors for optimized electrode function.

Expanded Pipeline and Immunoassay CapabilitiesBuilding on a dozen+ technologies ready for clinical validation, IVD’s versatile platform now incorporates immunoassay expansions for integrated chronic disease monitoring. This multi-biomarker approach targets high-demand indications in diabetes, cardiovascular health, liver/kidney function, anemia, and more—focusing on regions like the Americas, Europe, Asia-Pacific, China, India, and Africa.

Our VisionWith a robust IP portfolio and prototypes demonstrating superior performance, IVD is accelerating commercialization through collaborations that expedite market entry. We envision a world where advanced diagnostics are universally accessible, reducing barriers to proactive care and empowering healthier lives.